Health Catalyst, Inc Common Stock
Here’s whether Health Catalyst, Inc Common Stock (HCAT) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+3.25% over 10 days). Concerns: trading below the 200-day MA (long-term downtrend); RSI 88 — overbought, elevated pullback risk; weak 1-year return of -49.7%; rising volume on a downtrend (distribution, 2.25x avg). Currently 55.0% off its 52-week high. Score: -2/7.
HCAT is trading below its 200-day MA ($2.21) — a key warning sign the longer-term trend is under pressure. With an RSI of 87.8, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -49.7% compares to +24.4% for SPY (trailed the market by 74.1%). The current 55.0% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.